Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.

These two controlled clinical pharmacology studies assessed cagrilintide exposure in participants with varying renal and hepatic function and found no clinically relevant differences versus normal function. The authors note the small sample sizes as a limitation. The data are directly relevant to safe dosing of the peptide in special populations and were well tolerated.